Industry Research Reports

Home > Reports > Service & Software > Global Neuroimaging Software Market Research Report 2026

Global Neuroimaging Software Market Research Report 2026

Industry: Service & Software

Published Date: 2026-08-14

Pages: 209 Pages

Report ld: 6528103

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

biaoTi KEY FINDINGS

Europe has the densest specialist supplier base, while North America combines major imaging platforms with leading neurovascular and surgical-planning vendors

Stroke and cerebrovascular imaging remain commercially established applications, while neurodegenerative monitoring is becoming a more important source of incremental demand

MRI-based quantification is expanding from diagnostic assessment toward treatment eligibility, longitudinal monitoring and ARIA evaluation

Neuroimaging Software Market Size(US$)

CAGR 2026-2032

10.3%

Market Size,2032

USD 2,638

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 1,466 million

Market Forecast in 2032(Value)

US$ 2,638 million

CAGR

10.3%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Neuroimaging Software market was valued at US$ 1326 million in 2025 and is anticipated to reach US$ 2638 million by 2032, at a CAGR of 10.3% from 2026 to 2032.

Neuroimaging Software refers to specialized medical software used to process, quantify, visualize, interpret, and manage analytical outputs derived from imaging of the brain and central nervous system. The market primarily covers software applied to MRI and its advanced sequences, CT/CTA/CTP, PET, SPECT, and multimodal neuroimaging datasets. Core capabilities include image registration and correction, automated tissue and lesion segmentation, brain volumetry and morphometry, perfusion analysis, diffusion and tractography processing, functional brain mapping, molecular imaging quantification, longitudinal change assessment, AI-assisted abnormality detection, and structured reporting. Commercial products are delivered through on-premise workstations, server-based applications, cloud or SaaS platforms, identifiable advanced post-processing modules integrated into imaging environments, and specialized analytical platforms supporting clinical trials and neuroscience research. Neuroimaging Software is primarily used in stroke and cerebrovascular disease, Alzheimer’s disease and other neurodegenerative disorders, multiple sclerosis, neuro-oncology, epilepsy, neurosurgical planning, functional brain assessment, and CNS drug development. The market is characterized by a combination of regulated clinical software, specialized quantitative imaging tools, AI-enabled decision-support applications, and research-oriented commercial platforms.

biaoTi MARKET TRENDS

Neuroimaging Software is shifting from isolated post-processing tools and single-purpose algorithms toward integrated, multimodal and longitudinal analytical workflows. MRI remains central to quantitative brain analysis, while CT-based stroke applications, PET and SPECT quantification, diffusion imaging, functional MRI and multimodal fusion broaden the addressable clinical workflows. Product development is increasingly focused on automated segmentation, quantitative biomarkers, longitudinal comparison, structured reporting and cloud-enabled delivery rather than stand-alone visualization alone. The expansion of disease-modifying therapies for Alzheimer’s disease is also strengthening the role of quantitative MRI and treatment-safety monitoring. In August 2025, the U.S. FDA required an additional earlier MRI monitoring point for patients receiving lecanemab because of ARIA risk, reinforcing the importance of repeatable brain-image assessment during therapy. At the same time, consolidation is accelerating as larger imaging and digital-health groups acquire specialized analytical technologies: GE HealthCare completed its acquisition of icometrix in 2025, SyntheticMR completed its acquisition of Combinostics, and RadNet acquired Gleamer for integration into DeepHealth in March 2026.

MARKET SEGMENTATION

By Company

GE HealthCare
Siemens Healthineers
RapidAI
Viz.ai
Philips
Brainlab
Canon
Fujifilm
Brainomix
Bruker
Cortechs.ai
RadNet
Aidoc
ConcertAI
Qure.ai
United Imaging Intelligence
Shukun Technology
Infervision
Stryker
Nicolab
Avicenna.AI
Synaptive Medical
Quibim
Surgical Theater
mediaire
Qynapse
Thermo Fisher
Hermes Medical Solutions
Omniscient Neurotechnology
IQ-AI
Neurophet
LPIXEL
JLK
Brainreader
NordicNeuroLab
VUNO
Heuron
Coreline Soft
Cercare Medical

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Advanced Post-processing and Visualization
Quantitative Biomarkers and Volumetry
AI Detection
Molecular Neuroimaging Quantification
Others

Segment by Application

Stroke and Cerebrovascular Disease
Neurodegenerative Disease and Multiple Sclerosis
Neuro-oncology
Others

Segment by Category

On-premise
Cloud-based
Hybrid

Segment by Division

Clinical Diagnostic or Decision Support
Clinical Trial or Drug Development
Research Use Only
Others

biaoTi MARKET DYNAMICS

Drivers

Demand for Neuroimaging Software is being supported by the rising clinical need for faster and more standardized interpretation of complex neurological imaging, together with increasing use of quantitative biomarkers in stroke, dementia, multiple sclerosis, neuro-oncology and neurosurgical planning. Hospital systems are seeking tools that reduce manual measurement, improve consistency across readers and accelerate time-sensitive workflows, particularly in acute stroke. Another important driver is the growing role of imaging in treatment selection and safety monitoring for neurodegenerative therapies. FDA requirements for additional MRI monitoring during lecanemab therapy illustrate how imaging is becoming more closely connected to longitudinal therapeutic management rather than one-time diagnosis alone. CNS drug development also creates demand for standardized MRI and PET analysis across sites and time points, supporting specialized clinical-trial imaging and biomarker platforms.

Restraints

Market adoption remains constrained by fragmented reimbursement, lengthy hospital procurement cycles, regulatory requirements, interoperability issues and the cost of integrating analytical software into existing radiology and clinical workflows. Neuroimaging algorithms must also perform consistently across scanners, protocols, patient populations and imaging quality levels, increasing the cost of validation and product maintenance. In research-oriented applications, widely used academic and open-source software continues to limit pricing power for commercial vendors. Large imaging OEMs can also bundle advanced post-processing functions into broader workstation or enterprise-imaging contracts, which can reduce the addressable stand-alone software value for independent suppliers. These factors mean that technically strong products do not automatically translate into rapid commercial adoption, particularly where the clinical workflow benefit or reimbursement pathway is not clearly defined.

Opportunities

The most attractive opportunities are emerging where Neuroimaging Software moves beyond image visualization to support treatment pathways, measurable biomarkers and longitudinal disease management. Quantitative MRI for Alzheimer’s disease, ARIA assessment, automated brain volumetry, multiple-sclerosis monitoring, PET-based neurodegenerative biomarkers and treatment-response analysis are becoming increasingly relevant. CMS documentation on automated brain MRI detection and quantification identifies regulated commercial products for brain volumetry, ARIA analysis and morphometric assessment, demonstrating that these applications are moving toward identifiable clinical software categories. Additional opportunities exist in vendor-neutral cloud deployment, multimodal MRI/PET analysis, CNS clinical trials, smaller hospitals that lack specialist neuroradiology resources, and emerging Asian markets where domestic medical-AI suppliers are building localized neuroimaging products.

Challenges

The principal long-term challenge is converting algorithmic performance into repeatable clinical and economic value. Regulatory clearance alone does not guarantee reimbursement, workflow adoption or sustained usage, and suppliers must continuously demonstrate reliability across diverse populations and imaging environments. Competitive intensity is also rising as specialized algorithms become integrated into larger enterprise-imaging, AI-orchestration and scanner-vendor ecosystems. Consolidation may increase access to distribution while simultaneously reducing the number of independent purchasing decisions available to smaller vendors. Data privacy requirements, cross-border cloud deployment rules, cybersecurity expectations and evolving AI regulation add further complexity. The market therefore favors companies that can combine validated algorithms with clinical integration, scalable deployment, regulatory execution and durable relationships with hospitals or pharmaceutical customers.

biaoTi VALUE CHAIN ANALYSIS

The Neuroimaging Software value chain begins with medical imaging data, computational infrastructure, image-processing frameworks, anatomical atlases, clinically annotated datasets and algorithm-development capabilities. These inputs support the development of segmentation, registration, volumetric analysis, perfusion modeling, diffusion analysis, functional mapping, molecular imaging quantification and AI-based detection tools. The midstream layer consists of specialized software companies, medical-imaging OEMs, clinical AI developers, nuclear-medicine software providers, neurosurgical planning vendors and CNS imaging platforms. Products are commercialized through perpetual or term licenses, enterprise subscriptions, SaaS contracts, per-scan or usage-based models, OEM embedding arrangements and clinical-trial contracts.

Value is created when raw imaging data are converted into quantitative measurements, biomarkers, workflow prioritization, treatment-planning information or longitudinal evidence that improves decision consistency and reduces manual analytical work. Downstream users include hospitals, imaging centers, neurology and neurosurgery departments, pharmaceutical and biotechnology companies, CROs and research institutions. Cost structures are dominated by software R&D, clinical validation, regulatory compliance, data acquisition and curation, cloud infrastructure, cybersecurity, integration, sales and implementation. As deployment moves toward recurring SaaS and enterprise models, scalable software economics become more important, but clinical support, integration and regulatory maintenance remain meaningful cost components.

biaoTi SEGMENT INSIGHTS

From a product-function perspective, the market contains several commercially meaningful segments rather than a single homogeneous software category. Acute stroke and neurovascular analysis is one of the most established clinical applications because software outputs can be integrated directly into time-sensitive emergency workflows. Advanced post-processing and visualization also represent an established installed-base segment through major imaging vendors. Quantitative brain MRI, neurodegenerative disease assessment and longitudinal biomarker analysis are gaining strategic importance as neurological treatment pathways increasingly require repeatable measurements rather than qualitative interpretation alone. MRI-related applications represent the broadest product coverage across the identified supplier universe, spanning structural volumetry, diffusion imaging, functional mapping, perfusion, multiple-sclerosis analysis and neuro-oncology.

The fastest-evolving opportunity set is concentrated around quantitative and treatment-linked applications rather than basic image viewing. Automated brain segmentation, hippocampal and regional volumetry, cortical and lesion measurement, ARIA assessment and longitudinal change analysis are becoming increasingly differentiated commercial functions. CMS documentation recognizes multiple FDA-cleared products addressing automated labeling, visualization and volumetric quantification of brain MRI, as well as dedicated ARIA analysis, supporting the emergence of a more defined regulated quantitative-neuroimaging segment. Functional MRI, DTI, tractography, connectomics and molecular neuroimaging remain smaller but technically differentiated segments with strong relevance in neurosurgery, research and CNS drug development.

biaoTi DOWNSTREAM MARKET OPPORTUNITIES

Hospitals and diagnostic imaging centers remain the primary commercial users of Neuroimaging Software, but the demand profile is widening beyond the radiology department. Stroke centers require rapid neurovascular triage and perfusion analysis, neurology services increasingly use quantitative MRI for neurodegenerative and demyelinating diseases, and neurosurgical teams require multimodal fusion, tractography and functional mapping for preoperative planning. Pharmaceutical and biotechnology companies represent an increasingly strategic downstream opportunity because CNS drug programs depend on standardized longitudinal imaging biomarkers, patient stratification and safety monitoring. This creates room for software suppliers that can bridge routine clinical imaging and research-grade quantitative analysis. Smaller hospitals and imaging networks also represent an underpenetrated opportunity as cloud-based deployment reduces the need for dedicated local workstations and specialist post-processing resources.

biaoTi REGIONAL INSIGHTS

Fastest-Growing Region: Asia Pacific

Europe has the largest concentration of identified independent specialist Neuroimaging Software suppliers, particularly in quantitative brain MRI, perfusion, nuclear medicine, functional imaging and neurodegenerative disease analysis. The region combines established medical-imaging technology clusters with a relatively broad base of smaller specialist developers. North America has a different competitive structure: major imaging and digital-health platforms coexist with commercially advanced stroke-AI, neurosurgical planning, quantitative imaging and research-software providers. The region remains particularly important for regulated clinical commercialization because FDA clearance, large hospital networks and pharmaceutical demand can support broader deployment of successful products. CMS activity around automated brain MRI quantification also highlights increasing attention to the clinical and reimbursement framework for quantitative neuroimaging.

XX.X
%
CAGR*
XXXX
US$ Million
XXXX
REGIONAL SHARE

BY TYPE,2021-2032(US $ MILLION)

Advanced Post-processing and Visualization

Quantitative Biomarkers and Volumetry

AI Detection

Molecular Neuroimaging Quantification

Others

BY APPLICATION，2021-2032(US $ MILLION）

Stroke and Cerebrovascular Disease

Neurodegenerative Disease and Multiple Sclerosis

Neuro-oncology

Others

Asia-Pacific is becoming more strategically important but remains structurally fragmented. Japan combines global imaging OEMs with domestic neurological AI developers, while South Korea has developed a relatively dense cluster of specialist brain-imaging AI companies focused on volumetry, stroke, Parkinson’s disease, intracranial hemorrhage and cerebrovascular analysis. China has a growing medical-AI ecosystem, although the stricter product-evidence standard applied in this study results in a smaller Core Formal List than in Europe or North America. Taiwan and Australia contribute several niche vendors in diffusion MRI, brain metastasis analysis, perfusion and quantitative neuroimaging. The regional opportunity therefore lies less in simple geographic expansion and more in localization, regulatory approval, hospital integration and adaptation to country-specific clinical workflows.

biaoTi COMPETITIVE LANDSCAPE ANALYSIS

The Neuroimaging Software market has a layered competitive structure rather than a single group of directly comparable competitors. Major imaging OEMs compete through scanner installed bases, integrated workstations, enterprise-imaging relationships and global distribution, while independent specialists compete through deeper algorithms and clinical focus in stroke, brain volumetry, neurodegeneration, perfusion, molecular imaging, fMRI/DTI, neuro-oncology and neurosurgical planning. The study identifies 61 companies in the Core Formal List, demonstrating that the commercially relevant supplier base extends well beyond a small group of global imaging companies. Competitive consolidation is increasing as larger platforms acquire specialized software capabilities. GE HealthCare closed its acquisition of icometrix in 2025 to strengthen neurological MRI analysis, SyntheticMR acquired Combinostics to broaden quantitative neuroimaging capabilities, and RadNet acquired Gleamer in 2026 to expand DeepHealth’s clinical AI portfolio. These transactions point toward continued integration of specialist algorithms into broader imaging ecosystems, but highly differentiated areas such as ARIA quantification, connectomics, advanced perfusion, molecular imaging and functional brain mapping continue to provide defensible positions for focused vendors.

biaoTi REPORT SCOPE

This report delivers a comprehensive overview of the global Neuroimaging Software market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuroimaging Software. The Neuroimaging Software market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Neuroimaging Software market comprehensively. Regional market sizes by Type, by Application, by Deployment Model, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Neuroimaging Software manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Deployment Model, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.

Chapter 3: Provides a detailed view of the competitive landscape for Neuroimaging Software companies, covering revenue share, development plans, and mergers and acquisitions.

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.

Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.

Chapter 12: Key findings and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuroimaging Software Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Advanced Post-processing and Visualization

1.2.3 Quantitative Biomarkers and Volumetry

1.2.4 AI Detection

1.2.5 Molecular Neuroimaging Quantification

1.2.6 Others

1.3 Market by Deployment Model

1.3.1 Global Neuroimaging Software Market Size Growth Rate by Deployment Model: 2021 vs 2025 vs 2032

1.3.2 On-premise

1.3.3 Cloud-based

1.3.4 Hybrid

1.4 Market by Intended Use

1.4.1 Global Neuroimaging Software Market Size Growth Rate by Intended Use: 2021 vs 2025 vs 2032

1.4.2 Clinical Diagnostic or Decision Support

1.4.3 Clinical Trial or Drug Development

1.4.4 Research Use Only

1.4.5 Others

1.5 Market by Application

1.5.1 Global Neuroimaging Software Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Stroke and Cerebrovascular Disease

1.5.3 Neurodegenerative Disease and Multiple Sclerosis

1.5.4 Neuro-oncology

1.5.5 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Neuroimaging Software Market Perspective (2021–2032)

2.2 Global Neuroimaging Software Growth Trends by Region

2.2.1 Global Neuroimaging Software Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Neuroimaging Software Historic Market Size by Region (2021–2026)

2.2.3 Neuroimaging Software Forecasted Market Size by Region (2027–2032)

2.3 Neuroimaging Software Market Dynamics

2.3.1 Neuroimaging Software Industry Trends

2.3.2 Neuroimaging Software Market Drivers

2.3.3 Neuroimaging Software Market Challenges

2.3.4 Neuroimaging Software Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neuroimaging Software Players by Revenue

3.1.1 Global Top Neuroimaging Software Players by Revenue (2021–2026)

3.1.2 Global Neuroimaging Software Revenue Market Share by Players (2021–2026)

3.2 Global Top Neuroimaging Software Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Neuroimaging Software Revenue

3.4 Global Neuroimaging Software Market Concentration Ratio

3.4.1 Global Neuroimaging Software Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuroimaging Software Revenue in 2025

3.5 Global Key Players of Neuroimaging Software Head Offices and Areas Served

3.6 Global Key Players of Neuroimaging Software, Products and Applications

3.7 Global Key Players of Neuroimaging Software, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Neuroimaging Software Breakdown Data by Type

4.1 Global Neuroimaging Software Historic Market Size by Type (2021–2026)

4.2 Global Neuroimaging Software Forecasted Market Size by Type (2027–2032)

5 Neuroimaging Software Breakdown Data by Application

5.1 Global Neuroimaging Software Historic Market Size by Application (2021–2026)

5.2 Global Neuroimaging Software Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Neuroimaging Software Market Size (2021–2032)

6.2 North America Neuroimaging Software Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Neuroimaging Software Market Size by Country (2021–2026)

6.4 North America Neuroimaging Software Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neuroimaging Software Market Size (2021–2032)

7.2 Europe Neuroimaging Software Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Neuroimaging Software Market Size by Country (2021–2026)

7.4 Europe Neuroimaging Software Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Neuroimaging Software Market Size (2021–2032)

8.2 Asia-Pacific Neuroimaging Software Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Neuroimaging Software Market Size by Region (2021–2026)

8.4 Asia-Pacific Neuroimaging Software Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Neuroimaging Software Market Size (2021–2032)

9.2 Latin America Neuroimaging Software Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Neuroimaging Software Market Size by Country (2021–2026)

9.4 Latin America Neuroimaging Software Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neuroimaging Software Market Size (2021–2032)

10.2 Middle East & Africa Neuroimaging Software Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Neuroimaging Software Market Size by Country (2021–2026)

10.4 Middle East & Africa Neuroimaging Software Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GE HealthCare

11.1.1 GE HealthCare Company Details

11.1.2 GE HealthCare Business Overview

11.1.3 GE HealthCare Neuroimaging Software Introduction

11.1.4 GE HealthCare Revenue in Neuroimaging Software Business (2021–2026)

11.1.5 GE HealthCare Recent Development

11.2 Siemens Healthineers

11.2.1 Siemens Healthineers Company Details

11.2.2 Siemens Healthineers Business Overview

11.2.3 Siemens Healthineers Neuroimaging Software Introduction

11.2.4 Siemens Healthineers Revenue in Neuroimaging Software Business (2021–2026)

11.2.5 Siemens Healthineers Recent Development

11.3 RapidAI

11.3.1 RapidAI Company Details

11.3.2 RapidAI Business Overview

11.3.3 RapidAI Neuroimaging Software Introduction

11.3.4 RapidAI Revenue in Neuroimaging Software Business (2021–2026)

11.3.5 RapidAI Recent Development

11.4 Viz.ai

11.4.1 Viz.ai Company Details

11.4.2 Viz.ai Business Overview

11.4.3 Viz.ai Neuroimaging Software Introduction

11.4.4 Viz.ai Revenue in Neuroimaging Software Business (2021–2026)

11.4.5 Viz.ai Recent Development

11.5 Philips

11.5.1 Philips Company Details

11.5.2 Philips Business Overview

11.5.3 Philips Neuroimaging Software Introduction

11.5.4 Philips Revenue in Neuroimaging Software Business (2021–2026)

11.5.5 Philips Recent Development

11.6 Brainlab

11.6.1 Brainlab Company Details

11.6.2 Brainlab Business Overview

11.6.3 Brainlab Neuroimaging Software Introduction

11.6.4 Brainlab Revenue in Neuroimaging Software Business (2021–2026)

11.6.5 Brainlab Recent Development

11.7 Canon

11.7.1 Canon Company Details

11.7.2 Canon Business Overview

11.7.3 Canon Neuroimaging Software Introduction

11.7.4 Canon Revenue in Neuroimaging Software Business (2021–2026)

11.7.5 Canon Recent Development

11.8 Fujifilm

11.8.1 Fujifilm Company Details

11.8.2 Fujifilm Business Overview

11.8.3 Fujifilm Neuroimaging Software Introduction

11.8.4 Fujifilm Revenue in Neuroimaging Software Business (2021–2026)

11.8.5 Fujifilm Recent Development

11.9 Brainomix

11.9.1 Brainomix Company Details

11.9.2 Brainomix Business Overview

11.9.3 Brainomix Neuroimaging Software Introduction

11.9.4 Brainomix Revenue in Neuroimaging Software Business (2021–2026)

11.9.5 Brainomix Recent Development

11.10 Bruker

11.10.1 Bruker Company Details

11.10.2 Bruker Business Overview

11.10.3 Bruker Neuroimaging Software Introduction

11.10.4 Bruker Revenue in Neuroimaging Software Business (2021–2026)

11.10.5 Bruker Recent Development

11.11 Cortechs.ai

11.11.1 Cortechs.ai Company Details

11.11.2 Cortechs.ai Business Overview

11.11.3 Cortechs.ai Neuroimaging Software Introduction

11.11.4 Cortechs.ai Revenue in Neuroimaging Software Business (2021–2026)

11.11.5 Cortechs.ai Recent Development

11.12 RadNet

11.12.1 RadNet Company Details

11.12.2 RadNet Business Overview

11.12.3 RadNet Neuroimaging Software Introduction

11.12.4 RadNet Revenue in Neuroimaging Software Business (2021–2026)

11.12.5 RadNet Recent Development

11.13 Aidoc

11.13.1 Aidoc Company Details

11.13.2 Aidoc Business Overview

11.13.3 Aidoc Neuroimaging Software Introduction

11.13.4 Aidoc Revenue in Neuroimaging Software Business (2021–2026)

11.13.5 Aidoc Recent Development

11.14 ConcertAI

11.14.1 ConcertAI Company Details

11.14.2 ConcertAI Business Overview

11.14.3 ConcertAI Neuroimaging Software Introduction

11.14.4 ConcertAI Revenue in Neuroimaging Software Business (2021–2026)

11.14.5 ConcertAI Recent Development

11.15 Qure.ai

11.15.1 Qure.ai Company Details

11.15.2 Qure.ai Business Overview

11.15.3 Qure.ai Neuroimaging Software Introduction

11.15.4 Qure.ai Revenue in Neuroimaging Software Business (2021–2026)

11.15.5 Qure.ai Recent Development

11.16 United Imaging Intelligence

11.16.1 United Imaging Intelligence Company Details

11.16.2 United Imaging Intelligence Business Overview

11.16.3 United Imaging Intelligence Neuroimaging Software Introduction

11.16.4 United Imaging Intelligence Revenue in Neuroimaging Software Business (2021–2026)

11.16.5 United Imaging Intelligence Recent Development

11.17 Shukun Technology

11.17.1 Shukun Technology Company Details

11.17.2 Shukun Technology Business Overview

11.17.3 Shukun Technology Neuroimaging Software Introduction

11.17.4 Shukun Technology Revenue in Neuroimaging Software Business (2021–2026)

11.17.5 Shukun Technology Recent Development

11.18 Infervision

11.18.1 Infervision Company Details

11.18.2 Infervision Business Overview

11.18.3 Infervision Neuroimaging Software Introduction

11.18.4 Infervision Revenue in Neuroimaging Software Business (2021–2026)

11.18.5 Infervision Recent Development

11.19 Stryker

11.19.1 Stryker Company Details

11.19.2 Stryker Business Overview

11.19.3 Stryker Neuroimaging Software Introduction

11.19.4 Stryker Revenue in Neuroimaging Software Business (2021–2026)

11.19.5 Stryker Recent Development

11.20 Nicolab

11.20.1 Nicolab Company Details

11.20.2 Nicolab Business Overview

11.20.3 Nicolab Neuroimaging Software Introduction

11.20.4 Nicolab Revenue in Neuroimaging Software Business (2021–2026)

11.20.5 Nicolab Recent Development

11.21 Avicenna.AI

11.21.1 Avicenna.AI Company Details

11.21.2 Avicenna.AI Business Overview

11.21.3 Avicenna.AI Neuroimaging Software Introduction

11.21.4 Avicenna.AI Revenue in Neuroimaging Software Business (2021–2026)

11.21.5 Avicenna.AI Recent Development

11.22 Synaptive Medical

11.22.1 Synaptive Medical Company Details

11.22.2 Synaptive Medical Business Overview

11.22.3 Synaptive Medical Neuroimaging Software Introduction

11.22.4 Synaptive Medical Revenue in Neuroimaging Software Business (2021–2026)

11.22.5 Synaptive Medical Recent Development

11.23 Quibim

11.23.1 Quibim Company Details

11.23.2 Quibim Business Overview

11.23.3 Quibim Neuroimaging Software Introduction

11.23.4 Quibim Revenue in Neuroimaging Software Business (2021–2026)

11.23.5 Quibim Recent Development

11.24 Surgical Theater

11.24.1 Surgical Theater Company Details

11.24.2 Surgical Theater Business Overview

11.24.3 Surgical Theater Neuroimaging Software Introduction

11.24.4 Surgical Theater Revenue in Neuroimaging Software Business (2021–2026)

11.24.5 Surgical Theater Recent Development

11.25 mediaire

11.25.1 mediaire Company Details

11.25.2 mediaire Business Overview

11.25.3 mediaire Neuroimaging Software Introduction

11.25.4 mediaire Revenue in Neuroimaging Software Business (2021–2026)

11.25.5 mediaire Recent Development

11.26 Qynapse

11.26.1 Qynapse Company Details

11.26.2 Qynapse Business Overview

11.26.3 Qynapse Neuroimaging Software Introduction

11.26.4 Qynapse Revenue in Neuroimaging Software Business (2021–2026)

11.26.5 Qynapse Recent Development

11.27 Thermo Fisher

11.27.1 Thermo Fisher Company Details

11.27.2 Thermo Fisher Business Overview

11.27.3 Thermo Fisher Neuroimaging Software Introduction

11.27.4 Thermo Fisher Revenue in Neuroimaging Software Business (2021–2026)

11.27.5 Thermo Fisher Recent Development

11.28 Hermes Medical Solutions

11.28.1 Hermes Medical Solutions Company Details

11.28.2 Hermes Medical Solutions Business Overview

11.28.3 Hermes Medical Solutions Neuroimaging Software Introduction

11.28.4 Hermes Medical Solutions Revenue in Neuroimaging Software Business (2021–2026)

11.28.5 Hermes Medical Solutions Recent Development

11.29 Omniscient Neurotechnology

11.29.1 Omniscient Neurotechnology Company Details

11.29.2 Omniscient Neurotechnology Business Overview

11.29.3 Omniscient Neurotechnology Neuroimaging Software Introduction

11.29.4 Omniscient Neurotechnology Revenue in Neuroimaging Software Business (2021–2026)

11.29.5 Omniscient Neurotechnology Recent Development

11.30 IQ-AI

11.30.1 IQ-AI Company Details

11.30.2 IQ-AI Business Overview

11.30.3 IQ-AI Neuroimaging Software Introduction

11.30.4 IQ-AI Revenue in Neuroimaging Software Business (2021–2026)

11.30.5 IQ-AI Recent Development

11.31 Neurophet

11.31.1 Neurophet Company Details

11.31.2 Neurophet Business Overview

11.31.3 Neurophet Neuroimaging Software Introduction

11.31.4 Neurophet Revenue in Neuroimaging Software Business (2021–2026)

11.31.5 Neurophet Recent Development

11.32 LPIXEL

11.32.1 LPIXEL Company Details

11.32.2 LPIXEL Business Overview

11.32.3 LPIXEL Neuroimaging Software Introduction

11.32.4 LPIXEL Revenue in Neuroimaging Software Business (2021–2026)

11.32.5 LPIXEL Recent Development

11.33 JLK

11.33.1 JLK Company Details

11.33.2 JLK Business Overview

11.33.3 JLK Neuroimaging Software Introduction

11.33.4 JLK Revenue in Neuroimaging Software Business (2021–2026)

11.33.5 JLK Recent Development

11.34 Brainreader

11.34.1 Brainreader Company Details

11.34.2 Brainreader Business Overview

11.34.3 Brainreader Neuroimaging Software Introduction

11.34.4 Brainreader Revenue in Neuroimaging Software Business (2021–2026)

11.34.5 Brainreader Recent Development

11.35 NordicNeuroLab

11.35.1 NordicNeuroLab Company Details

11.35.2 NordicNeuroLab Business Overview

11.35.3 NordicNeuroLab Neuroimaging Software Introduction

11.35.4 NordicNeuroLab Revenue in Neuroimaging Software Business (2021–2026)

11.35.5 NordicNeuroLab Recent Development

11.36 VUNO

11.36.1 VUNO Company Details

11.36.2 VUNO Business Overview

11.36.3 VUNO Neuroimaging Software Introduction

11.36.4 VUNO Revenue in Neuroimaging Software Business (2021–2026)

11.36.5 VUNO Recent Development

11.37 Heuron

11.37.1 Heuron Company Details

11.37.2 Heuron Business Overview

11.37.3 Heuron Neuroimaging Software Introduction

11.37.4 Heuron Revenue in Neuroimaging Software Business (2021–2026)

11.37.5 Heuron Recent Development

11.38 Coreline Soft

11.38.1 Coreline Soft Company Details

11.38.2 Coreline Soft Business Overview

11.38.3 Coreline Soft Neuroimaging Software Introduction

11.38.4 Coreline Soft Revenue in Neuroimaging Software Business (2021–2026)

11.38.5 Coreline Soft Recent Development

11.39 Cercare Medical

11.39.1 Cercare Medical Company Details

11.39.2 Cercare Medical Business Overview

11.39.3 Cercare Medical Neuroimaging Software Introduction

11.39.4 Cercare Medical Revenue in Neuroimaging Software Business (2021–2026)

11.39.5 Cercare Medical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Neuroimaging Software Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Advanced Post-processing and Visualization

Table 3. Key Players of Quantitative Biomarkers and Volumetry

Table 4. Key Players of AI Detection

Table 5. Key Players of Molecular Neuroimaging Quantification

Table 6. Key Players of Others

Table 7. Global Neuroimaging Software Market Size Growth Rate by Deployment Model (US$ Million): 2021 vs 2025 vs 2032

Table 8. Key Players of On-premise

Table 9. Key Players of Cloud-based

Table 10. Key Players of Hybrid

Table 11. Global Neuroimaging Software Market Size Growth Rate by Intended Use (US$ Million): 2021 vs 2025 vs 2032

Table 12. Key Players of Clinical Diagnostic or Decision Support

Table 13. Key Players of Clinical Trial or Drug Development

Table 14. Key Players of Research Use Only

Table 15. Key Players of Others

Table 16. Global Neuroimaging Software Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Neuroimaging Software Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 18. Global Neuroimaging Software Market Size by Region (US$ Million), 2021–2026

Table 19. Global Neuroimaging Software Market Share by Region (2021–2026)

Table 20. Global Neuroimaging Software Forecasted Market Size by Region (US$ Million), 2027–2032

Table 21. Global Neuroimaging Software Market Share by Region (2027–2032)

Table 22. Neuroimaging Software Market Trends

Table 23. Neuroimaging Software Market Drivers

Table 24. Neuroimaging Software Market Challenges

Table 25. Neuroimaging Software Market Restraints

Table 26. Global Neuroimaging Software Revenue by Players (US$ Million), 2021–2026

Table 27. Global Neuroimaging Software Market Share by Players (2021–2026)

Table 28. Global Top Neuroimaging Software Players by Tier (Tier 1, Tier 2, and Tier 3), based on Neuroimaging Software Revenue, 2025

Table 29. Ranking of Global Top Neuroimaging Software Companies by Revenue (US$ Million) in 2025

Table 30. Global 5 Largest Players Market Share by Neuroimaging Software Revenue (CR5 and HHI), 2021–2026

Table 31. Global Key Players of Neuroimaging Software, Headquarters and Area Served

Table 32. Global Key Players of Neuroimaging Software, Products and Applications

Table 33. Global Key Players of Neuroimaging Software, Date of General Availability (GA)

Table 34. Mergers and Acquisitions, Expansion Plans

Table 35. Global Neuroimaging Software Market Size by Type (US$ Million), 2021–2026

Table 36. Global Neuroimaging Software Revenue Market Share by Type (2021–2026)

Table 37. Global Neuroimaging Software Forecasted Market Size by Type (US$ Million), 2027–2032

Table 38. Global Neuroimaging Software Revenue Market Share by Type (2027–2032)

Table 39. Global Neuroimaging Software Market Size by Application (US$ Million), 2021–2026

Table 40. Global Neuroimaging Software Revenue Market Share by Application (2021–2026)

Table 41. Global Neuroimaging Software Forecasted Market Size by Application (US$ Million), 2027–2032

Table 42. Global Neuroimaging Software Revenue Market Share by Application (2027–2032)

Table 43. North America Neuroimaging Software Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. North America Neuroimaging Software Market Size by Country (US$ Million), 2021–2026

Table 45. North America Neuroimaging Software Market Size by Country (US$ Million), 2027–2032

Table 46. Europe Neuroimaging Software Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 47. Europe Neuroimaging Software Market Size by Country (US$ Million), 2021–2026

Table 48. Europe Neuroimaging Software Market Size by Country (US$ Million), 2027–2032

Table 49. Asia-Pacific Neuroimaging Software Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 50. Asia-Pacific Neuroimaging Software Market Size by Region (US$ Million), 2021–2026

Table 51. Asia-Pacific Neuroimaging Software Market Size by Region (US$ Million), 2027–2032

Table 52. Latin America Neuroimaging Software Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 53. Latin America Neuroimaging Software Market Size by Country (US$ Million), 2021–2026

Table 54. Latin America Neuroimaging Software Market Size by Country (US$ Million), 2027–2032

Table 55. Middle East & Africa Neuroimaging Software Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 56. Middle East & Africa Neuroimaging Software Market Size by Country (US$ Million), 2021–2026

Table 57. Middle East & Africa Neuroimaging Software Market Size by Country (US$ Million), 2027–2032

Table 58. GE HealthCare Company Details

Table 59. GE HealthCare Business Overview

Table 60. GE HealthCare Neuroimaging Software Product

Table 61. GE HealthCare Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 62. GE HealthCare Recent Development

Table 63. Siemens Healthineers Company Details

Table 64. Siemens Healthineers Business Overview

Table 65. Siemens Healthineers Neuroimaging Software Product

Table 66. Siemens Healthineers Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 67. Siemens Healthineers Recent Development

Table 68. RapidAI Company Details

Table 69. RapidAI Business Overview

Table 70. RapidAI Neuroimaging Software Product

Table 71. RapidAI Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 72. RapidAI Recent Development

Table 73. Viz.ai Company Details

Table 74. Viz.ai Business Overview

Table 75. Viz.ai Neuroimaging Software Product

Table 76. Viz.ai Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 77. Viz.ai Recent Development

Table 78. Philips Company Details

Table 79. Philips Business Overview

Table 80. Philips Neuroimaging Software Product

Table 81. Philips Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 82. Philips Recent Development

Table 83. Brainlab Company Details

Table 84. Brainlab Business Overview

Table 85. Brainlab Neuroimaging Software Product

Table 86. Brainlab Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 87. Brainlab Recent Development

Table 88. Canon Company Details

Table 89. Canon Business Overview

Table 90. Canon Neuroimaging Software Product

Table 91. Canon Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 92. Canon Recent Development

Table 93. Fujifilm Company Details

Table 94. Fujifilm Business Overview

Table 95. Fujifilm Neuroimaging Software Product

Table 96. Fujifilm Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 97. Fujifilm Recent Development

Table 98. Brainomix Company Details

Table 99. Brainomix Business Overview

Table 100. Brainomix Neuroimaging Software Product

Table 101. Brainomix Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 102. Brainomix Recent Development

Table 103. Bruker Company Details

Table 104. Bruker Business Overview

Table 105. Bruker Neuroimaging Software Product

Table 106. Bruker Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 107. Bruker Recent Development

Table 108. Cortechs.ai Company Details

Table 109. Cortechs.ai Business Overview

Table 110. Cortechs.ai Neuroimaging Software Product

Table 111. Cortechs.ai Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 112. Cortechs.ai Recent Development

Table 113. RadNet Company Details

Table 114. RadNet Business Overview

Table 115. RadNet Neuroimaging Software Product

Table 116. RadNet Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 117. RadNet Recent Development

Table 118. Aidoc Company Details

Table 119. Aidoc Business Overview

Table 120. Aidoc Neuroimaging Software Product

Table 121. Aidoc Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 122. Aidoc Recent Development

Table 123. ConcertAI Company Details

Table 124. ConcertAI Business Overview

Table 125. ConcertAI Neuroimaging Software Product

Table 126. ConcertAI Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 127. ConcertAI Recent Development

Table 128. Qure.ai Company Details

Table 129. Qure.ai Business Overview

Table 130. Qure.ai Neuroimaging Software Product

Table 131. Qure.ai Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 132. Qure.ai Recent Development

Table 133. United Imaging Intelligence Company Details

Table 134. United Imaging Intelligence Business Overview

Table 135. United Imaging Intelligence Neuroimaging Software Product

Table 136. United Imaging Intelligence Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 137. United Imaging Intelligence Recent Development

Table 138. Shukun Technology Company Details

Table 139. Shukun Technology Business Overview

Table 140. Shukun Technology Neuroimaging Software Product

Table 141. Shukun Technology Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 142. Shukun Technology Recent Development

Table 143. Infervision Company Details

Table 144. Infervision Business Overview

Table 145. Infervision Neuroimaging Software Product

Table 146. Infervision Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 147. Infervision Recent Development

Table 148. Stryker Company Details

Table 149. Stryker Business Overview

Table 150. Stryker Neuroimaging Software Product

Table 151. Stryker Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 152. Stryker Recent Development

Table 153. Nicolab Company Details

Table 154. Nicolab Business Overview

Table 155. Nicolab Neuroimaging Software Product

Table 156. Nicolab Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 157. Nicolab Recent Development

Table 158. Avicenna.AI Company Details

Table 159. Avicenna.AI Business Overview

Table 160. Avicenna.AI Neuroimaging Software Product

Table 161. Avicenna.AI Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 162. Avicenna.AI Recent Development

Table 163. Synaptive Medical Company Details

Table 164. Synaptive Medical Business Overview

Table 165. Synaptive Medical Neuroimaging Software Product

Table 166. Synaptive Medical Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 167. Synaptive Medical Recent Development

Table 168. Quibim Company Details

Table 169. Quibim Business Overview

Table 170. Quibim Neuroimaging Software Product

Table 171. Quibim Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 172. Quibim Recent Development

Table 173. Surgical Theater Company Details

Table 174. Surgical Theater Business Overview

Table 175. Surgical Theater Neuroimaging Software Product

Table 176. Surgical Theater Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 177. Surgical Theater Recent Development

Table 178. mediaire Company Details

Table 179. mediaire Business Overview

Table 180. mediaire Neuroimaging Software Product

Table 181. mediaire Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 182. mediaire Recent Development

Table 183. Qynapse Company Details

Table 184. Qynapse Business Overview

Table 185. Qynapse Neuroimaging Software Product

Table 186. Qynapse Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 187. Qynapse Recent Development

Table 188. Thermo Fisher Company Details

Table 189. Thermo Fisher Business Overview

Table 190. Thermo Fisher Neuroimaging Software Product

Table 191. Thermo Fisher Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 192. Thermo Fisher Recent Development

Table 193. Hermes Medical Solutions Company Details

Table 194. Hermes Medical Solutions Business Overview

Table 195. Hermes Medical Solutions Neuroimaging Software Product

Table 196. Hermes Medical Solutions Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 197. Hermes Medical Solutions Recent Development

Table 198. Omniscient Neurotechnology Company Details

Table 199. Omniscient Neurotechnology Business Overview

Table 200. Omniscient Neurotechnology Neuroimaging Software Product

Table 201. Omniscient Neurotechnology Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 202. Omniscient Neurotechnology Recent Development

Table 203. IQ-AI Company Details

Table 204. IQ-AI Business Overview

Table 205. IQ-AI Neuroimaging Software Product

Table 206. IQ-AI Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 207. IQ-AI Recent Development

Table 208. Neurophet Company Details

Table 209. Neurophet Business Overview

Table 210. Neurophet Neuroimaging Software Product

Table 211. Neurophet Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 212. Neurophet Recent Development

Table 213. LPIXEL Company Details

Table 214. LPIXEL Business Overview

Table 215. LPIXEL Neuroimaging Software Product

Table 216. LPIXEL Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 217. LPIXEL Recent Development

Table 218. JLK Company Details

Table 219. JLK Business Overview

Table 220. JLK Neuroimaging Software Product

Table 221. JLK Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 222. JLK Recent Development

Table 223. Brainreader Company Details

Table 224. Brainreader Business Overview

Table 225. Brainreader Neuroimaging Software Product

Table 226. Brainreader Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 227. Brainreader Recent Development

Table 228. NordicNeuroLab Company Details

Table 229. NordicNeuroLab Business Overview

Table 230. NordicNeuroLab Neuroimaging Software Product

Table 231. NordicNeuroLab Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 232. NordicNeuroLab Recent Development

Table 233. VUNO Company Details

Table 234. VUNO Business Overview

Table 235. VUNO Neuroimaging Software Product

Table 236. VUNO Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 237. VUNO Recent Development

Table 238. Heuron Company Details

Table 239. Heuron Business Overview

Table 240. Heuron Neuroimaging Software Product

Table 241. Heuron Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 242. Heuron Recent Development

Table 243. Coreline Soft Company Details

Table 244. Coreline Soft Business Overview

Table 245. Coreline Soft Neuroimaging Software Product

Table 246. Coreline Soft Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 247. Coreline Soft Recent Development

Table 248. Cercare Medical Company Details

Table 249. Cercare Medical Business Overview

Table 250. Cercare Medical Neuroimaging Software Product

Table 251. Cercare Medical Revenue in Neuroimaging Software Business (US$ Million), 2021–2026

Table 252. Cercare Medical Recent Development

Table 253. Research Programs/Design for This Report

Table 254. Key Data Information from Secondary Sources

Table 255. Key Data Information from Primary Sources

Table 256. Authors List of This Report

List of Figures

Figure 1. Neuroimaging Software Picture

Figure 2. Global Neuroimaging Software Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Neuroimaging Software Market Share by Type: 2025 vs 2032

Figure 4. Advanced Post-processing and Visualization Features

Figure 5. Quantitative Biomarkers and Volumetry Features

Figure 6. AI Detection Features

Figure 7. Molecular Neuroimaging Quantification Features

Figure 8. Others Features

Figure 9. Global Neuroimaging Software Market Size Comparison by Deployment Model (US$ Million), 2021–2032

Figure 10. On-premise Features

Figure 11. Cloud-based Features

Figure 12. Hybrid Features

Figure 13. Global Neuroimaging Software Market Size Comparison by Intended Use (US$ Million), 2021–2032

Figure 14. Clinical Diagnostic or Decision Support Features

Figure 15. Clinical Trial or Drug Development Features

Figure 16. Research Use Only Features

Figure 17. Others Features

Figure 18. Global Neuroimaging Software Market Size by Application (US$ Million), 2021–2032

Figure 19. Global Neuroimaging Software Market Share by Application: 2025 vs 2032

Figure 20. Stroke and Cerebrovascular Disease Case Studies

Figure 21. Neurodegenerative Disease and Multiple Sclerosis Case Studies

Figure 22. Neuro-oncology Case Studies

Figure 23. Others Case Studies

Figure 24. Neuroimaging Software Report Years Considered

Figure 25. Global Neuroimaging Software Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 26. Global Neuroimaging Software Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 27. Global Neuroimaging Software Market Share by Region: 2025 vs 2032

Figure 28. Global Neuroimaging Software Market Share by Players in 2025

Figure 29. Global Neuroimaging Software Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 30. The Top 10 and 5 Players Market Share by Neuroimaging Software Revenue in 2025

Figure 31. North America Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. North America Neuroimaging Software Market Share by Country (2021–2032)

Figure 33. United States Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Canada Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Europe Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Europe Neuroimaging Software Market Share by Country (2021–2032)

Figure 37. Germany Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. France Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. U.K. Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Italy Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Russia Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Ireland Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Asia-Pacific Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Asia-Pacific Neuroimaging Software Market Share by Region (2021–2032)

Figure 45. China Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Japan Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. South Korea Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Southeast Asia Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. India Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Australia & New Zealand Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Latin America Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. Latin America Neuroimaging Software Market Share by Country (2021–2032)

Figure 53. Mexico Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Brazil Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Middle East & Africa Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 56. Middle East & Africa Neuroimaging Software Market Share by Country (2021–2032)

Figure 57. Israel Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 58. Saudi Arabia Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 59. UAE Neuroimaging Software Market Size YoY Growth (US$ Million), 2021–2032

Figure 60. GE HealthCare Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 61. Siemens Healthineers Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 62. RapidAI Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 63. Viz.ai Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 64. Philips Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 65. Brainlab Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 66. Canon Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 67. Fujifilm Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 68. Brainomix Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 69. Bruker Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 70. Cortechs.ai Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 71. RadNet Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 72. Aidoc Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 73. ConcertAI Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 74. Qure.ai Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 75. United Imaging Intelligence Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 76. Shukun Technology Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 77. Infervision Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 78. Stryker Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 79. Nicolab Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 80. Avicenna.AI Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 81. Synaptive Medical Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 82. Quibim Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 83. Surgical Theater Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 84. mediaire Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 85. Qynapse Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 86. Thermo Fisher Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 87. Hermes Medical Solutions Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 88. Omniscient Neurotechnology Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 89. IQ-AI Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 90. Neurophet Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 91. LPIXEL Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 92. JLK Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 93. Brainreader Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 94. NordicNeuroLab Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 95. VUNO Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 96. Heuron Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 97. Coreline Soft Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 98. Cercare Medical Revenue Growth Rate in Neuroimaging Software Business (2021–2026)

Figure 99. Bottom-up and Top-down Approaches for This Report

Figure 100. Data Triangulation

Figure 101. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Neuroimaging Software market? zhanKai

The top companies in the global Neuroimaging Software market are GE HealthCare、Siemens Healthineers、RapidAI.

What was the global market size of Neuroimaging Software in 2032? shouQi

What is the annual compound growth rate of the global Neuroimaging Software market size from 2026 to 2032? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of Neuroimaging Software in 2026? shouQi

Related Reports

Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neuroimaging Software market is projected to grow from US$ 1326 million in 2025 to US$ 2638 million by 2032, at a CAGR of 10.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-08-14
Pages: 208
USD 4900.00
(Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neuroimaging Software market size was US$ 1326 million in 2025 and is forecast to reach a readjusted size of US$ 2638 million by 2032 with a CAGR of 10.3% during the forecast period 2026-2032.
Published Date: 2026-08-14
Pages: 199
USD 4250.00
(Single User License)
Neuroimaging Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neuroimaging Software was estimated to be worth US$ 1326 million in 2025 and is projected to reach US$ 2638 million, growing at a CAGR of 10.3% from 2026 to 2032.
Published Date: 2026-08-14
Pages: 206
USD 3950.00
(Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neuroimaging Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-11-17
Pages: 76
USD 4250.00
(Single User License)
Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neuroimaging Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-16
Pages: 130
USD 4900.00
(Single User License)
Global Neuroimaging Software Market Research Report 2025
The global market for Neuroimaging Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-04
Pages: 75
USD 2900.00
(Single User License)
Neuroimaging Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neuroimaging Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-04
Pages: 95
USD 3950.00
(Single User License)

Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neuroimaging Software market is projected to grow from US$ 1326 million in 2025 to US$ 2638 million by 2032, at a CAGR of 10.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-08-14
Pages: 208
USD 4900.00 (Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neuroimaging Software market size was US$ 1326 million in 2025 and is forecast to reach a readjusted size of US$ 2638 million by 2032 with a CAGR of 10.3% during the forecast period 2026-2032.
Published: 2026-08-14
Pages: 199
USD 4250.00 (Single User License)
Neuroimaging Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neuroimaging Software was estimated to be worth US$ 1326 million in 2025 and is projected to reach US$ 2638 million, growing at a CAGR of 10.3% from 2026 to 2032.
Published: 2026-08-14
Pages: 206
USD 3950.00 (Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neuroimaging Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-11-17
Pages: 76
USD 4250.00 (Single User License)
Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neuroimaging Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-16
Pages: 130
USD 4900.00 (Single User License)
Global Neuroimaging Software Market Research Report 2025
The global market for Neuroimaging Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-04
Pages: 75
USD 2900.00 (Single User License)
Neuroimaging Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neuroimaging Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-04
Pages: 95
USD 3950.00 (Single User License)